Celldex Therapeutics (CLDX) Short term Debt (2010 - 2013)

Celldex Therapeutics' Short term Debt history runs 4 years deep, the most recent figure standing at $5.6 million for Q1 2013.

• In Q1 2013, Short term Debt rose 6.35% year-over-year to $5.6 million; the TTM figure through Mar 2013 stood at $5.6 million (up 6.35% YoY), while the FY2012 annual figure was $5.6 million, down 8.87% from the prior year.
• Short term Debt was $5.6 million for Q1 2013 at Celldex Therapeutics, up from $5.6 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $6.1 million in Q4 2011 to a low of $1.1 million in Q4 2010.
• Historically, Short term Debt has averaged $4.8 million across 4 years, with a median of $5.3 million in 2012.
• The sharpest annual moves came in 2011 and 2012: Short term Debt surged 452.3% in 2011, then dropped 8.87% in 2012.
• A 4-year view of Short term Debt shows it stood at $1.1 million in 2010, then soared by 452.3% to $6.1 million in 2011, then decreased by 8.87% to $5.6 million in 2012, then grew by 0.68% to $5.6 million in 2013.
• The last three Short term Debt figures came in at $5.6 million (Q1 2013), $5.6 million (Q4 2012), and $5.3 million (Q3 2012), per Business Quant data.